BiotechTube

Roxadustat + Darbepoetin alfa

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anemia in Chronic Kidney Disease in Non-dialysis Patients

Conditions

Anemia in Chronic Kidney Disease in Non-dialysis Patients

Trial Timeline

Mar 12, 2014 → Nov 6, 2019

NCT ID
NCT02021318

About Roxadustat + Darbepoetin alfa

Roxadustat + Darbepoetin alfa is a phase 3 stage product being developed by Astellas Pharma for Anemia in Chronic Kidney Disease in Non-dialysis Patients. The current trial status is completed. This product is registered under clinical trial identifier NCT02021318. Target conditions include Anemia in Chronic Kidney Disease in Non-dialysis Patients.

What happened to similar drugs?

20 of 20 similar drugs in Anemia in Chronic Kidney Disease in Non-dialysis Patients were approved

Approved (20) Terminated (5) Active (0)
✅Aranesp®AmgenApproved
✅Epoetin alfa 450 IU/kg once a week + Epoetin alfa 150 IU/kg 3 times a week + Epoetin alfa 450 IU/kg once a week (QW) + Epoetin alfa 150 IU/kg 3 times a week (TIW)Johnson & JohnsonApproved
✅Epoetin AlfaJohnson & JohnsonApproved
✅Roxadustat + rHuEPOAstraZenecaApproved
✅ICL670 + Chelation + No chelationNovartisApproved
✅cera, darbepoetin, epoetin-beta + ESARocheApproved
✅methoxy polyethylene glycol-epoetin beta [Mircera]RocheApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT02952092Phase 3Completed
NCT02021318Phase 3Completed
NCT01888445Phase 2Completed

Competing Products

20 competing products in Anemia in Chronic Kidney Disease in Non-dialysis Patients

See all competitors
ProductCompanyStageHype Score
Aranesp®AmgenApproved
43
KER-047Keros TherapeuticsPhase 2
17
LY2787106Eli LillyPhase 1
29
R744 + R744Chugai PharmaceuticalPhase 3
40
epoetin beta + placeboChugai PharmaceuticalPhase 3
40
recombinant human erythropoietin + recombinant human erythropoietin placeboChugai PharmaceuticalPhase 3
40
recombinant human erythropoietin + recombinant human erythropoietinChugai PharmaceuticalPhase 3
40
darbepoetin alfaAmgenPhase 3
40
PrasugrelDaiichi SankyoPhase 1
29
Prasugrel + PlaceboDaiichi SankyoPhase 2
35
roxadustatAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
AlefaceptAstellas PharmaPhase 1
21
RoxadustatAstellas PharmaPhase 2
35
roxadustatAstellas PharmaPhase 1
29
Roxadustat + PlaceboAstellas PharmaPhase 3
40
RoxadustatAstellas PharmaPre-clinical
26
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
40
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40